Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Caribou Biosciences Inc (NASDAQ: CRBU) was $1.59 for the day, up 0.63% from the previous closing price of $1.58. In other words, the price has increased by $0.63 from its previous closing price. On the day, 1.04 million shares were traded. CRBU stock price reached its highest trading level at $1.6399 during the session, while it also had its lowest trading level at $1.5613.
Ratios:
Our analysis of CRBU’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.54 and its Current Ratio is at 5.54. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In the most recent recommendation for the company, Evercore ISI on June 03, 2024, Downgraded its rating to In-line and sets its target price to $3 from $13 previously.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.Evercore ISI initiated its Outperform rating on October 31, 2023, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 14 ’25 when Haurwitz Rachel E. bought 20,000 shares for $1.02 per share. The transaction valued at 20,400 led to the insider holds 3,369,395 shares of the business.
MCCLUNG BARBARA G sold 3,564 shares of CRBU for $4,811 on Feb 21 ’25. The Chief Legal Officer now owns 443,502 shares after completing the transaction at $1.35 per share. On Feb 21 ’25, another insider, Khan Ruhi Ahmad, who serves as the Chief Business Officer of the company, sold 3,564 shares for $1.35 each. As a result, the insider received 4,811 and left with 66,936 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 148614192 and an Enterprise Value of 26819180. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.00 while its Price-to-Book (P/B) ratio in mrq is 1.05. Its current Enterprise Value per Revenue stands at 2.885 whereas that against EBITDA is -0.198.
Stock Price History:
The Beta on a monthly basis for CRBU is 2.62, which has changed by 0.0063694715 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, CRBU has reached a high of $3.54, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -13.90%, while the 200-Day Moving Average is calculated to be -3.98%.
Shares Statistics:
CRBU traded an average of 2.23M shares per day over the past three months and 1071520 shares per day over the past ten days. A total of 93.47M shares are outstanding, with a floating share count of 82.78M. Insiders hold about 11.44% of the company’s shares, while institutions hold 37.02% stake in the company. Shares short for CRBU as of 1767139200 were 6501051 with a Short Ratio of 2.92, compared to 1764288000 on 6140242. Therefore, it implies a Short% of Shares Outstanding of 6501051 and a Short% of Float of 7.28.
Earnings Estimates
Caribou Biosciences Inc (CRBU) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.3 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.5 and -$1.65 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.35, with 8.0 analysts recommending between -$0.87 and -$1.73.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $2.65M. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 7 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $10.49M, while the lowest revenue estimate was $7.2M, resulting in an average revenue estimate of $9.45M. In the same quarter a year ago, actual revenue was $9.99M
